Abcellera Biologics Operating Margin vs. Net Income
| ABCL Stock | USD 3.04 0.18 5.59% |
Abcellera Biologics Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.59 | 0.78 |
|
|
For Abcellera Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Abcellera Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Abcellera Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Abcellera Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Abcellera Biologics over time as well as its relative position and ranking within its peers.
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Biologics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Abcellera Biologics Revenue Breakdown by Earning Segment
By analyzing Abcellera Biologics' earnings estimates, investors can diagnose different trends across Abcellera Biologics' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Abcellera Biologics Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Abcellera Biologics's current stock value. Our valuation model uses many indicators to compare Abcellera Biologics value to that of its competitors to determine the firm's financial worth. Abcellera Biologics is rated fourth in operating margin category among its peers. It is rated below average in net income category among its peers . At this time, Abcellera Biologics' Operating Profit Margin is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Abcellera Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Abcellera Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Abcellera Biologics |
| = | (8.52) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Abcellera Biologics |
| = | (162.86 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Abcellera Net Income Comparison
Abcellera Biologics is currently under evaluation in net income category among its peers.
Abcellera Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Abcellera Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Abcellera Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Abcellera Biologics' change in net profit over the period of time. It can combine multiple indicators of Abcellera Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.9 M | -3.7 M | |
| Net Interest Income | 44.2 M | 46.5 M | |
| Interest Income | 44.2 M | 46.5 M | |
| Operating Income | -283.3 M | -269.1 M | |
| Net Loss | -146.6 M | -139.2 M | |
| Income Before Tax | -180.4 M | -171.3 M | |
| Total Other Income Expense Net | 131.5 M | 138.1 M | |
| Net Income Applicable To Common Shares | 182.3 M | 94.4 M | |
| Net Loss | -146.6 M | -139.2 M | |
| Income Tax Expense | -33.8 M | -32.1 M | |
| Non Operating Income Net Other | 26 M | 20.5 M | |
| Change To Netincome | 64.3 M | 67.5 M | |
| Net Loss | (0.64) | (0.60) | |
| Income Quality | 0.77 | 0.73 | |
| Net Income Per E B T | 0.73 | 0.60 |
Abcellera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Abcellera Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Abcellera Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Abcellera Biologics' important profitability drivers and their relationship over time.
Abcellera Biologics Earnings Estimation Breakdown
The calculation of Abcellera Biologics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Abcellera Biologics is estimated to be -0.15875 with the future projection ranging from a low of -0.1625 to a high of -0.155. Please be aware that this consensus of annual earnings estimates for Abcellera Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.16 Lowest | Expected EPS | -0.15 Highest |
Abcellera Biologics Earnings Projection Consensus
Suppose the current estimates of Abcellera Biologics' value are higher than the current market price of the Abcellera Biologics stock. In this case, investors may conclude that Abcellera Biologics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Abcellera Biologics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 8 | 50.0% | 0.0 | -0.15875 | -0.57 |
Abcellera Biologics Earnings per Share Projection vs Actual
Actual Earning per Share of Abcellera Biologics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Abcellera Biologics predict the company's earnings will be in the future. The higher the earnings per share of Abcellera Biologics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Abcellera Biologics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Abcellera Biologics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Abcellera Biologics should always be considered in relation to other companies to make a more educated investment decision.Abcellera Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Abcellera Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.14 | -0.19 | -0.05 | 35 | ||
2025-08-07 | 2025-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2025-05-05 | 2025-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2025-02-18 | 2024-12-31 | -0.1471 | -0.12 | 0.0271 | 18 | ||
2024-11-04 | 2024-09-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-08-06 | 2024-06-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2024-05-07 | 2024-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2024-02-20 | 2023-12-31 | -0.13 | -0.17 | -0.04 | 30 | ||
2023-11-02 | 2023-09-30 | -0.13 | -0.1 | 0.03 | 23 | ||
2023-08-03 | 2023-06-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2023-05-04 | 2023-03-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2023-02-21 | 2022-12-31 | -0.01 | -0.1 | -0.09 | 900 | ||
2022-11-08 | 2022-09-30 | 0.05 | 0.08 | 0.03 | 60 | ||
2022-08-09 | 2022-06-30 | -0.02 | -0.02 | 0.0 | 0 | ||
2022-05-10 | 2022-03-31 | 0.38 | 0.54 | 0.16 | 42 | ||
2022-02-24 | 2021-12-31 | 0.19 | 0.19 | 0.0 | 0 | ||
2021-11-09 | 2021-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2021-08-12 | 2021-06-30 | 0.08 | -0.01 | -0.09 | 112 | ||
2021-05-13 | 2021-03-31 | 0.38 | 0.37 | -0.01 | 2 | ||
2021-03-29 | 2020-12-31 | 0.61 | 0.44 | -0.17 | 27 | ||
2020-12-14 | 2020-09-30 | -0.02 | -0.04 | -0.02 | 100 | ||
2020-06-30 | 2020-03-31 | 0 | 0.0102 | 0.0102 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | 0.0102 | 0.0102 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -0.0108 | -0.0108 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | 2.0E-4 | 2.0E-4 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.002 | -0.002 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.002 | -0.002 | 0 |
Use Abcellera Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abcellera Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abcellera Biologics will appreciate offsetting losses from the drop in the long position's value.Abcellera Biologics Pair Trading
Abcellera Biologics Pair Trading Analysis
The ability to find closely correlated positions to Abcellera Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abcellera Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abcellera Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abcellera Biologics to buy it.
The correlation of Abcellera Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abcellera Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abcellera Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abcellera Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Abcellera Biologics position
In addition to having Abcellera Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Exotic Funds Thematic Idea Now
Exotic Funds
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
To fully project Abcellera Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Abcellera Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Abcellera Biologics' income statement, its balance sheet, and the statement of cash flows.